Statistics from Altmetric.com
Podocalyxin, a CD34-related transmembrane sialomucin that is expressed on haematopoietic progenitors, vascular endothelia and kidney podocytes, has been detected in the development of some of the more aggressive forms of cancer.1 2 Immunohistochemical assessment of podocalyxin expression might be useful to evaluate the aggressive forms of thyroid cancers. In this study, podocalyxin expression was studied in 238 thyroid tumours, and was identified only in undifferentiated thyroid carcinomas (UTCs). In cases of coexisting undifferentiated and differentiated thyroid carcinomas, podocalyxin immunohistochemistry is helpful to distinguish UTCs from other differentiated carcinomas.
Various thyroid tumours constituting a total of 238 cases were selected from the surgical …